316 related articles for article (PubMed ID: 16680149)
1. Eradication of established tumors in mice by a combination antibody-based therapy.
Uno T; Takeda K; Kojima Y; Yoshizawa H; Akiba H; Mittler RS; Gejyo F; Okumura K; Yagita H; Smyth MJ
Nat Med; 2006 Jun; 12(6):693-8. PubMed ID: 16680149
[TBL] [Abstract][Full Text] [Related]
2. Involvement of tumor necrosis factor-related apoptosis-inducing ligand in NK cell-mediated and IFN-gamma-dependent suppression of subcutaneous tumor growth.
Takeda K; Smyth MJ; Cretney E; Hayakawa Y; Yamaguchi N; Yagita H; Okumura K
Cell Immunol; 2001 Dec; 214(2):194-200. PubMed ID: 12088418
[TBL] [Abstract][Full Text] [Related]
3. Role of tumor necrosis factor-related apoptosis-inducing ligand in immune response to influenza virus infection in mice.
Ishikawa E; Nakazawa M; Yoshinari M; Minami M
J Virol; 2005 Jun; 79(12):7658-63. PubMed ID: 15919918
[TBL] [Abstract][Full Text] [Related]
4. Combination therapy of established tumors by antibodies targeting immune activating and suppressing molecules.
Takeda K; Kojima Y; Uno T; Hayakawa Y; Teng MW; Yoshizawa H; Yagita H; Gejyo F; Okumura K; Smyth MJ
J Immunol; 2010 May; 184(10):5493-501. PubMed ID: 20400706
[TBL] [Abstract][Full Text] [Related]
5. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity.
Ichikawa K; Liu W; Zhao L; Wang Z; Liu D; Ohtsuka T; Zhang H; Mountz JD; Koopman WJ; Kimberly RP; Zhou T
Nat Med; 2001 Aug; 7(8):954-60. PubMed ID: 11479629
[TBL] [Abstract][Full Text] [Related]
6. Cancer: novel therapeutic strategies that exploit the TNF-related apoptosis-inducing ligand (TRAIL)/TRAIL receptor pathway.
Cretney E; Takeda K; Smyth MJ
Int J Biochem Cell Biol; 2007; 39(2):280-6. PubMed ID: 17097329
[TBL] [Abstract][Full Text] [Related]
7. Are blockers of gp120/CD4 interaction effective inhibitors of HIV-1 immunopathogenesis?
Herbeuval JP; Shearer GM
AIDS Rev; 2006; 8(1):3-8. PubMed ID: 16736946
[TBL] [Abstract][Full Text] [Related]
8. Distinct function of monoclonal antibody to TRAIL-R2 as potentiator or inhibitor of the ligand TRAIL-induced apoptosis.
Mori E; Thomas M; Motoki K; Kataika S
FEBS Lett; 2005 Oct; 579(24):5379-84. PubMed ID: 16199041
[TBL] [Abstract][Full Text] [Related]
9. Complete regression of experimental solid tumors by combination LEC/chTNT-3 immunotherapy and CD25(+) T-cell depletion.
Li J; Hu P; Khawli LA; Epstein AL
Cancer Res; 2003 Dec; 63(23):8384-92. PubMed ID: 14679000
[TBL] [Abstract][Full Text] [Related]
10. Designed tumor necrosis factor-related apoptosis-inducing ligand variants initiating apoptosis exclusively via the DR5 receptor.
van der Sloot AM; Tur V; Szegezdi E; Mullally MM; Cool RH; Samali A; Serrano L; Quax WJ
Proc Natl Acad Sci U S A; 2006 Jun; 103(23):8634-9. PubMed ID: 16731632
[TBL] [Abstract][Full Text] [Related]
11. Targeted induction of apoptosis in cancer management: the emerging role of tumor necrosis factor-related apoptosis-inducing ligand receptor activating agents.
Rowinsky EK
J Clin Oncol; 2005 Dec; 23(36):9394-407. PubMed ID: 16361639
[TBL] [Abstract][Full Text] [Related]
12. Combined treatment of colorectal tumours with agonistic TRAIL receptor antibodies HGS-ETR1 and HGS-ETR2 and radiotherapy: enhanced effects in vitro and dose-dependent growth delay in vivo.
Marini P; Denzinger S; Schiller D; Kauder S; Welz S; Humphreys R; Daniel PT; Jendrossek V; Budach W; Belka C
Oncogene; 2006 Aug; 25(37):5145-54. PubMed ID: 16636678
[TBL] [Abstract][Full Text] [Related]
13. Impaired infiltration of tumor-specific cytolytic T cells in the absence of interferon-gamma despite their normal maturation in lymphoid organs during CD137 monoclonal antibody therapy.
Wilcox RA; Flies DB; Wang H; Tamada K; Johnson AJ; Pease LR; Rodriguez M; Guo Y; Chen L
Cancer Res; 2002 Aug; 62(15):4413-8. PubMed ID: 12154048
[TBL] [Abstract][Full Text] [Related]
14. Activation of tumor-specific CD8+ T Cells after intratumoral Ad5-TRAIL/CpG oligodeoxynucleotide combination therapy.
VanOosten RL; Griffith TS
Cancer Res; 2007 Dec; 67(24):11980-90. PubMed ID: 18089829
[TBL] [Abstract][Full Text] [Related]
15. CD11c+ dendritic cells and B cells contribute to the tumoricidal activity of anti-DR5 antibody therapy in established tumors.
Haynes NM; Hawkins ED; Li M; McLaughlin NM; Hämmerling GJ; Schwendener R; Winoto A; Wensky A; Yagita H; Takeda K; Kershaw MH; Darcy PK; Smyth MJ
J Immunol; 2010 Jul; 185(1):532-41. PubMed ID: 20505139
[TBL] [Abstract][Full Text] [Related]
16. Characterization of monoclonal antibodies directed against trail or trail receptors.
Vermot-Desroches C; Sergent E; Bonnin B; Wijdenes J
Cell Immunol; 2005; 236(1-2):86-91. PubMed ID: 16157319
[TBL] [Abstract][Full Text] [Related]
17. P-glycoprotein enhances TRAIL-triggered apoptosis in multidrug resistant cancer cells by interacting with the death receptor DR5.
Park SJ; Wu CH; Choi MR; Najafi F; Emami A; Safa AR
Biochem Pharmacol; 2006 Jul; 72(3):293-307. PubMed ID: 16753135
[TBL] [Abstract][Full Text] [Related]
18. Interferon gamma enhances the effectiveness of tumor necrosis factor-related apoptosis-inducing ligand receptor agonists in a xenograft model of Ewing's sarcoma.
Merchant MS; Yang X; Melchionda F; Romero M; Klein R; Thiele CJ; Tsokos M; Kontny HU; Mackall CL
Cancer Res; 2004 Nov; 64(22):8349-56. PubMed ID: 15548704
[TBL] [Abstract][Full Text] [Related]
19. Interferon (IFN)-gamma is a main mediator of keratinocyte (HaCaT) apoptosis and contributes to autocrine IFN-gamma and tumour necrosis factor-alpha production.
Konur A; Schulz U; Eissner G; Andreesen R; Holler E
Br J Dermatol; 2005 Jun; 152(6):1134-42. PubMed ID: 15948973
[TBL] [Abstract][Full Text] [Related]
20. Targeting death-inducing receptors in cancer therapy.
Takeda K; Stagg J; Yagita H; Okumura K; Smyth MJ
Oncogene; 2007 May; 26(25):3745-57. PubMed ID: 17530027
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]